Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of gut-associated halitosis with E. coli strain Nissle 1917 (Mutaflor)
2007-003756-11Phase 3Completed
- Sponsor
- Ardeypharm
- Start
- Jan 2009
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in halitosis comparing Mutaflor with Placebo (2 arms). Primary endpoint: Responder rate based on organoleptic score improvement at 8 weeks. Started Jan 2009; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
halitosis
Beyond the preview
Go deeper on 2007-003756-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003756-11.